Breaking News
May 21, 2018 - FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 21, 2018 - Infant death study reveals dangerous sleep practices among babysitters, relatives, others
May 21, 2018 - Intermittent fasting may increase diabetes risk, shows study
May 21, 2018 - New study shows declines in prostate cancer screening, diagnoses and treatment
May 21, 2018 - Fasting diets could raise risk of diabetes say experts
May 21, 2018 - FDA Alert: 7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall
May 21, 2018 - Cell phones at summer camp: Research explores the effects
May 21, 2018 - Birth rate decline driven by waiting longer to have children, cost of infertility treatment
May 21, 2018 - In-hospital opioid prescribing may increase post-discharge opioid use, shows study
May 21, 2018 - ABPI expert urges to find new ‘blockbuster treatments’ for brain tumors
May 21, 2018 - Disruption of Circadian Rhythm Negatively Impacts Mental Health
May 21, 2018 - Researchers reveal mechanisms of periodic paralysis in people with rare genetic disorder
May 21, 2018 - World first use of cognitive training reduces gait freezing in Parkinson’s patients
May 21, 2018 - NIH stops alcohol study that was looking at purported health benefits of drinking
May 21, 2018 - Higher belly fat levels linked to greater risk of vitamin D deficiency
May 21, 2018 - Scientists collate evidence for mismatch between past evolutionary adaptation and modern lives
May 21, 2018 - New case report reveals negative clinical impact of using biotin supplement
May 21, 2018 - Researchers discover new disease mechanism in chronic tobacco smokers
May 21, 2018 - Breast Cancer Patients May Shorten Herceptin Regimen: Study
May 21, 2018 - Bias keeps women with higher body weights away from the doctor: study
May 21, 2018 - Researchers identify protein essential for eye lens development and clear vision
May 21, 2018 - Frontal cortical lesions moderate response to prism adaptation treatment after stroke
May 21, 2018 - Ultrasound guidelines can reliably differentiate between pediatric thyroid nodules that require biopsy
May 21, 2018 - Weight loss is an important predictor of cancer
May 21, 2018 - Ozone exposure at birth linked to increased risk of developing asthma in childhood
May 21, 2018 - CT scan still effective to determine thrombectomy treatment in stroke, study shows
May 21, 2018 - Clot busting drug combo reduces risk of major strokes in high risk patients
May 21, 2018 - New airway transplantation technique shows promising results in lung cancer patients
May 21, 2018 - Biomarker blood test does not appear to curb antibiotic overuse, shows new study
May 21, 2018 - Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
May 21, 2018 - Grief symptoms similar in donor vs non-donor decision families
May 21, 2018 - Congo to start vaccinating populations against Ebola today to combat outbreak
May 21, 2018 - Researchers use MR spectroscopy to investigate mechanisms behind targeted treatment for gliomas
May 21, 2018 - Study reveals why older workers have higher stress levels than younger colleagues
May 21, 2018 - Health Tip: Taming a Pollen Allergy
May 21, 2018 - Inducing labor at 39 weeks reduces risks of C-section and other complications
May 20, 2018 - Developmental psychotherapy aims at helping antisocial adolescents become responsible adults
May 20, 2018 - People with OCD process emotions differently than their unaffected siblings
May 20, 2018 - Interfering with enzyme’s movement may be new approach for developing of anti-cancer drugs
May 20, 2018 - Prestroke and poststroke oral anticoagulation therapy in AF patients
May 20, 2018 - Why drug users prefer heroin at home, but cocaine while out
May 20, 2018 - Gene therapy that reverses blindness in dogs could also help treat humans
May 20, 2018 - Opioid-Related Payments Linked to Increase in Opioid Rx
May 20, 2018 - Phone apps push people to take their pills
May 20, 2018 - Backbreaking Work May Shorten Men’s Lives
May 20, 2018 - Harsher drug laws won’t stop violence, argues former police chief
May 20, 2018 - Cognitive decline in dementia is not reduced by exercise
May 20, 2018 - Detecting breast cancer with non-invasive ‘disease screening pill’
May 20, 2018 - Simple treatment may minimize hearing loss triggered by loud noises
May 20, 2018 - Alignment of mother and offspring body clock could prevent diseases such as heart disease and obesity
May 20, 2018 - New commercial data warehouse for life sciences
May 20, 2018 - Practice Intervention Targeting IV Opioids May Cut Exposure
May 20, 2018 - New study provides insight into blood signatures of inflammation
May 20, 2018 - Scientists make breakthrough discovery about vitamin B12
May 20, 2018 - What Causes Cancer? Misconceptions Abound
May 20, 2018 - Proper burial of dead cells limits inflammation
May 20, 2018 - Study offers novel solution to suppress metastatic spread of deadly breast cancer
May 20, 2018 - Perspectives of patients and caregivers on care transitions
May 20, 2018 - Guidelines for weight gain in pregnancy should be changed for underweight and very obese women
May 20, 2018 - Researchers transplant retinal sheets derived from human embryonic stem cells in retinal degeneration mouse models
May 20, 2018 - U.S. military personnel at greater risk for skin cancer than general population
May 20, 2018 - Your immune system holds the line against repeat invaders, thanks to this molecule
May 20, 2018 - Between death and deportation
May 20, 2018 - Developing a High Throughput Mass Spectrometry Platform for Drug Discovery
May 19, 2018 - New project aims to increase awareness among hospital clinicians of non-beneficial treatment at end-of-life
May 19, 2018 - Automated bone scan index offers accurate, speedy prognostic information about prostate cancer
May 19, 2018 - Rutgers Cancer Institute nurses research various topics to enhance patient experience
May 19, 2018 - Computer models provide valuable insight to structure and function of Ebola, Zika viruses
May 19, 2018 - Study exposes key tactic used by deadly fungus
May 19, 2018 - Bacterial signals are crucial to development of pre-leukemic myeloproliferation, study shows
May 19, 2018 - Global experts identify key issues in supporting children with brain injuries transition back to school
May 19, 2018 - Social connections may protect black men who have sex with men from acquiring HIV
May 19, 2018 - Study IDs Factors Linked to Quality of Life With Dementia
May 19, 2018 - Potassium — Consumer
May 19, 2018 - HIV-1 viruses transmitted at birth are resistant to antibodies in mother’s blood
May 19, 2018 - Some water pitchers are much better at removing toxins, shows research
May 19, 2018 - Scientists discover how unusually long strands of RNA help colon cancer cells avoid death
May 19, 2018 - International study finds viable treatment option for people with mild asthma
May 19, 2018 - Mayo discovery could enable development of personalized ovarian, brain cancer treatments
May 19, 2018 - ‘Superbug’ Surfaces at Poultry Farm in China
FDA grants approval for first drug to treat inherited breast cancer

FDA grants approval for first drug to treat inherited breast cancer

image_pdfDownload PDFimage_print

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.

“This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types.”

Breast cancer is the most common form of cancer in the United States. The National Cancer Institute at the National Institutes of Health estimates approximately 252,710 women will be diagnosed with breast cancer this year, and 40,610 will die of the disease. Approximately 20-25 percent of patients with hereditary breast cancers and 5-10 percent of patients with any type of breast cancer have a BRCA mutation. BRCA genes are involved with repairing damaged DNA and normally work to prevent tumor development. However, mutations of these genes may lead to certain cancers, including breast cancers.

Lynparza is a PARP (poly ADP-ribose polymerase) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth. Lynparza was first approved by the FDA in 2014 to treat certain patients with ovarian cancer and is now indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior hormonal (endocrine) therapy or be considered inappropriate for endocrine treatment.

Today, the FDA also expanded the approval of the BRACAnalysis CDx, an approved companion diagnostic to Lynparza, to include the detection of BRCA mutations in blood samples from patients with breast cancer.

The safety and efficacy of Lynparza for the treatment of breast cancer was based on a randomized clinical trial of 302 patients with HER2-negative metastatic breast cancer with a germline BRCA mutation. The trial measured the length of time the tumors did not have significant growth after treatment (progression-free survival). The median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only.

Common side effects of Lynparza include low levels of red blood cells (anemia), low levels of certain white blood cells (neutropenia, leukopenia), nausea, fatigue, vomiting, common cold (nasopharyngitis), respiratory tract infection, influenza, diarrhea, joint pain (arthralgia/myalgia), unusual taste sensation (dysgeusia), headache, indigestion (dyspepsia), decreased appetite, constipation and inflammation and sores in the mouth (stomatitis).

Severe side effects of Lynparza include development of certain blood or bone marrow cancers (myelodysplastic syndrome/acute myeloid leukemia) and inflammation in the lungs (pneumonitis). Lynparza can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception. Women taking Lynparza should not breastfeed as it could cause harm to a newborn baby.

This application was granted Priority Review, under which the FDA’s goal is to take action on an application within 6 months where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition.

Lynparza is also approved for the treatment of patients with BRCA-mutated, advanced ovarian cancer who have received three or more treatments of chemotherapy, and for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whose tumors have completely or partially responded to chemotherapy.

The FDA granted the approval of Lynparza to AstraZeneca Pharmaceuticals LP. The approval of the BRACAnalysis CDx was granted to Myriad Genetic Laboratories, Inc.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592347.htm

Tagged with:

About author

Related Articles